PharmaResearch Co., Ltd. (214450.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	603.0B	535.7B	350.1B	261.0B	194.8B
Cost of Revenue	148.9B	133.9B	98.9B	70.8B	60.6B
Gross Profit	454.7B	402.4B	251.2B	190.3B	134.1B
Operating Expenses
R&D Expense	30.1B	37.1B	21.2B	15.0B	8.7B
SG&A Expense	82.0B	103.6B	60.0B	74.4B	58.9B
General & Admin Expense	17.8B	19.8B	13.8B	10.1B	6.7B
Selling & Marketing Expense	64.2B	83.8B	46.1B	36.3B	29.5B
Other Expenses	118.5B	49.4B	44.0B	36.6B	648.6M
Total Operating Expenses	218.8B	190.1B	125.2B	89.4B	68.2B
Cost and Expenses	368.1B	324.0B	224.1B	168.8B	128.8B
Operating Income (EBIT)	235.5B	212.3B	126.1B	92.3B	65.9B
Non-Operating
Interest Income	17.8B	16.2B	10.2B	7.4B	5.3B
Interest Expense	10.4B	10.4B	4.6B	3.0B	3.8B
Net Interest Income	7.5B	5.8B	5.5B	4.4B	1.4B
Other Non-Op Income/Expense	21.1B	4.2B	(10.2B)	8.4B	(11.9B)
Non-Operating Income (excl Interest)	—	—	5.6B	(10.8B)	8.0B
EBT (Pre-Tax Income)	256.8B	216.5B	115.8B	100.7B	54.0B
Income Tax Expense	61.7B	48.3B	26.9B	23.4B	10.6B
Bottom Line
Net Income	185.7B	165.1B	92.0B	76.6B	40.6B
Earnings from Cont. Ops	195.2B	168.3B	88.9B	77.3B	43.4B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	188.4B	165.1B	92.0B	76.6B	40.6B
Per Share
Basic EPS	₩17,873	₩15,893	₩8,984	₩7,571	₩4,067
Diluted EPS	₩16,975	₩14,933	₩8,941	₩7,502	₩4,067
Revenue Per Share	₩58,392	₩51,561	₩34,008	₩25,579	₩19,523
Shares
Basic Shares Outstanding	10.3M	10.4M	10.3M	10.2M	10.0M
Diluted Shares Outstanding	10.3M	10.4M	10.6M	10.6M	10.0M
Profitability Metrics
EBITDA	197.4B	228.1B	134.1B	115.0B	76.5B
D&A	16.8B	15.8B	13.6B	12.0B	10.6B
EBIT	180.3B	212.3B	120.4B	103.0B	65.9B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026